Glucosamine, chondroitin, and manganese ascorbate for degenerative joint disease of the knee or low back: A randomized, double-blind, placebo- controlled pilot study

Military Medicine

Volumn 164, Issue 2, 1999, Pages 85-91

  Leffler, Christopher T ^a   Philippi, Alan F ^a   Leffler, Susan G ^b   Mosure, James C ^b   Kim, Peter D ^a  

^a Naval Amphibious Base Little Creek   (United States)

^b EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASCORBIC ACID; CHONDROITIN; COSAMIN; GLUCOSAMINE; MAGNESIUM; PARACETAMOL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; HUMAN; KNEE OSTEOARTHRITIS; MALE; OSTEOARTHRITIS; PAIN ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; SPONDYLOSIS;

EID: 0001954345     PISSN: 00264075     EISSN: None     Source Type: Journal    
DOI: 10.1093/milmed/164.2.85     Document Type: Article

References (47)

1. Resnick D, Niwayama G: Degenerative disease of extraspinal locations. In Diagnosis of Bone and Joint Disorders, Ed 3, pp 1263-371. Edited by Resnick D. Philadelphia, WB Saunders, 1995.
2. Mankin HJ, Brandt KD: Biochemistry and metabolism of articular cartilage in osteoarthritis. In Osteoarthritis: Diagnosis and Medical/Surgical Management, Ed 2, pp 109-54. Edited by Moskowitz RW, Howell DS, Goldberg VM, Mankin HJ. Philadelphia, WB Saunders, 1992.
3. Burkhardt D, Ghosh P: Laboratory evaluation of antiarthritic drugs as potential chondroprotective agents. Semin Arthritis Rheum 1987; 17(suppl 1): 3-34.
4. Brandt KD: Putting some muscle into osteoarthritis. Ann Intern Med 1997; 127: 154-6.
5. Rashad S, Revell P, Hemingway A, et al: Effect of non-steroidal anti-inflammatory drugs on the course of osteoarthritis. Lancet 1989; 519-22.
6. Pujalte JM, Llavore EP, Ylescupidez FR: Double-blind clinical evaluation of oral glucosamine sulphate in the basic treatment of osteoarthrosis. Curr Med Res Opin 1980; 7: 110-4.
7. Drovanti A, Bignamini AA, Rovati AL: Therapeutic activity of oral glucosamine sulfate in osteoarthritis: a placebo controlled double-blind investigation. Clin Ther 1980; 3: 260-72.
8. Giacovelli G, Rovati LC: Clinical efficacy of glucosamine sulfate in osteoarthritis of the spine [abstract]. Rev Esp Reumatol 1993; 20(suppl 1): Mo 96.
9. Noack W, Fischer M, Forster KK, et al: Glucosamine sulfate in osteoarthritis of the knee. Osteoarthritis Cartilage 1994; 2: 51-9.
10. Vajaradul Y: Double-blind clinical evaluation of intra-articular glucosamine in outpatients with gonarthrosis. Clin Ther 1981; 3: 336-43.
11. Reichelt A, Forster KK, Fischer M, et al: Efficacy and safety of intramuscular glucosamine sulfate in osteoarthritis of the knee: a randomised, placebo-controlled, double-blind study. Arzneim Forsch 1994; 44: 75-80.
12. Lopes Vaz A: Double-blind clinical evaluation of the relative efficacy of ibuprofen and glucosamine sulphate in the management of osteoarthrosis of the knee in out-patients. Curr Med Res Opin 1982; 8: 145-9.
13. Muller-Faßbender H, Bach GL, Haase W, et al: Glucosamine sulfate compared to ibuprofen in osteoarthritis of the knee. Osteoarthritis Cartilage 1994; 2: 61-9.
14. Crolle G. D'Este E: Glucosamine sulphate for the management of arthrosis: a controlled clinical investigation. Curr Med Res Opin 1980; 7: 104-9.
15. D'Ambrosio E, Casa B, Bompani R, et al: Glucosamine sulphate: a controlled clinical investigation in arthrosis. Pharmatherapeutica 1981; 2: 504-8.
16. Kerzberg EM, Roldan EJ, Castelli G, Huberman ED: Combination of glycosaminoglycans and acetylsalicylic acid in knee osteoarthrosis. Scand J Rheumatol 1987; 16: 377-80.
17. Rovetta G. Galactosaminoglycuronoglycan sulfate (matrix) in therapy of tibiofibular osteoarthritis of the knee. Drugs Exp Clin Res 1991; 17: 53-7.
18. Chevallard M, Galanti A, Paresce E, Wolf A, Carrabba M: Efficacy and tolerability of galactosamino-glycuronoglycan-sulfate in osteoarthritis of the knee: an 11-month experience. Int J Clin Pharmacol Res 1993; 13(suppl): 49-53.
19. Mazieres B, Loyau G, Menkes CJ, et al: Chondroitin sulfate in the treatment of gonarthrosis and coxarthrosis: a prospective multicenter placebo-controlled double-blind trial with five months follow-up. Rev Rhum Mal Osteoartic 1992; 59: 466-72.
20. Morreale P, Manopulo R, Galati M, et al: Comparison of the antiinflammatory efficacy of chondroitin sulfate and diclofenac sodium in patients with knee osteoarthritis. J Rheumatol 1996; 23: 1385-91.
21. Kellgren JH, Lawrence JS: Radiological assessment of osteoarthritis. Ann Rheum Dis 1957; 16:494-501.
22. Kellgren JH: The Epidemiology of Chronic Rheumatism, Vol II: Atlas of Standard Radiographs of Arthritis. Oxford, UK, Blackwell Scientific Publications, 1963.
23. Carette S, Leclaire R, Marcoux S, et al: Epidural corticosteroid injections for sciatica due to herniated nucleus pulposus. N Engl J Med 1997; 336: 1634-40.
24. Bradley JD, Brandt KD, Katz BP, et al: Comparison of an antiinflammatory dose of ibuprofen, an analgesic dose of ibuprofen, and acetaminophen in the treatment of patients with osteoarthritis of the knee. N Engl J Med 1991; 325: 87-91.
25. Lequesne MG, Mery C, Samson M, Gerard P: Indexes of severity for osteoarthritis of the hip and knee. Scand J Rheumatol Suppl 1987; 65: 85-9.
26. Roland M, Morris R: A study of the natural history of back pain. Part I. Development of a reliable and sensitive measure of disability in low-back pain. Spine 1983; 8: 141-4.
27. Husskisson E: Measurement of pain. Lancet 1974; 4: 1427.
28. Doyle DV, Dieppe PA, Scott J, Huskisson EC: An articular index for the assessment of osteoarthritis. Ann Rheum Dis 1981; 40: 75-8.
29. Lequesne M: Indices of severity and disease activity in osteoarthritis. Semin Arthritis Rheum 1991; 20: 48-54.
30. Gill K, Krag M, Johnson G, et al: Repeatability of four clinical methods for assessment of lumbar spinal motion. Spine 1988; 13: 50-3.
31. Armitage P, Berry G: Statistical Methods in Medical Research, Ed 3, pp 192-4, 245-9. Oxford, UK, Blackwell Scientific Publications, 1994.
32. Altman RD: Classification of disease: osteoarthritis. Semin Arthritis Rheum 1991; 20(suppl 2): 40-7.
33. Creamer P, Hochberg MC: Osteoarthritis. Lancet 1997; 350: 503-9
34. Cooper C, McAlindon T, Snow S, et al: Mechanical and constitutional risk factors for symptomatic knee osteoarthritis: differences between medial tibiofemoral and patellofemoral disease. J Rheumatol 1994; 21: 307-13.
35. Rejholec V: Long-term studies of antiosteoarthritic drugs: an assessment. Semin Arthritis Rheum 1987: 17(suppl 1): 35-53.
36. Resnick D, Niwayama G: Degenerative disease of the spine. In Diagnosis of Bone and Joint Disorders, Ed 3, pp 1372-462. Edited by Resnick D. Philadelphia, WB Saunders, 1995.
37. Setnikar I, Palumbo R, Canali S, Zanolo G: Pharmacokinetics of glucosamine in man. Arzneim Forsch 1993; 43: 1109-13.
38. Pavelka K Jr, Sedlackova M, Gatterova J, et al: Glycosaminoglycan polysulfuric acid (GAGPS) in osteoarthritis of the knee. Osteoarthritis Cartilage 1995; 3: 15-23.
39. Conte A, de Bernardi M, Palmieri L, et al: Metabolic fate of exogenous chondroitin sulfate in man. Arzneim Forsch 1991; 41: 768-72.
40. Conte A, Volpi N, Palmieri L, et al: Biochemical and pharmacokinetic aspects of oral treatment with chondroitin sulfate. Arzneim Forsch 1995; 45: 918-25.
41. Baici A, Horler D, Moser B, et al: Analysis of glycosaminoglycans in human serum after oral administration of chondroitin sulfate. Rheumatol Int 1992; 12: 81-8.
42. Hill J, Bird HA. Failure of selenium-ace to improve osteoarthritis. Br J Rheumatol 1990; 29: 211-3.
43. United States Pharmacopeial Convention Inc: USP DI, Vol 1 : Drug Information for the Health Care Professional, Ed 16, pp 469-73, 1956-7. Taunton, MA, Rand-McNally, 1996.
44. Tapadinhas MJ, Rivera IC, Bignamini AA: Oral glucosamine sulphate in the management of arthrosis: report on a multi-centre open investigation in Portugal. Pharmatherapeutica 1981; 3: 157-68.
45. Oliviero U, Sorrentino GP, De-Paola P, et al: Effects of the treatment with matrix on elderly people with chronic articular degeneration. Drugs Exp Clin Res 1991; 17: 45-51.
46. McNamara PS, Barr SC, Erb HN: Hematologic, hemostatic, and biochemical effects in dogs receiving an oral chondroprotective agent for thirty days. Am J Vet Res 1996: 57: 1390-4.
47. Gilman AG, Goodman LS, Rall TW, Murad F: The Pharmacological Basis of Therapeutics, Ed 7, p 1548. New York, McMillan, 1985.